Johnson & Johnson Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Johnson & Johnson share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 29.74M shares, a 176.13% increase from fiscal 2024.
- Johnson & Johnson share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 10.77M shares, a 13.04% decline from fiscal 2023.
- Johnson & Johnson share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 12.39M shares, a 24.06% decline from fiscal 2023.
- Johnson & Johnson share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 16.31M shares, a 23.11% increase from fiscal 2022.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2025-12-28 | 29.74M shares 10-K · filed 2026-02-11 | |
| 2024-12-29 | 10.77M shares 10-K · filed 2025-02-13 | |
| 2023-12-31 | 12.39M shares 10-K · filed 2024-02-16 | |
| 2023-01-01 | 16.31M shares 10-K · filed 2023-02-16 | |
| 2022-01-02 | 13.25M shares 10-K · filed 2023-02-16 | |
| 2021-01-03 | 16.27M shares 10-K · filed 2023-02-16 | |
| 2019-12-29 | 14.79M shares 10-K · filed 2022-02-17 | |
| 2018-12-30 | 16.23M shares 10-K · filed 2021-02-22 | |
| 2017-12-31 | 18.98M shares 10-K · filed 2020-02-18 | |
| 2017-01-01 | 22.55M shares 10-K · filed 2019-02-20 | |
| 2016-01-03 | 16.68M shares 10-K · filed 2018-02-21 | |
| 2014-12-28 | 25.32M shares 10-K · filed 2017-02-27 | |
| 2013-12-29 | 41.36M shares 10-K · filed 2016-02-24 | |
| 2012-12-30 | 49.39M shares 10-K · filed 2015-02-24 | |
| 2012-01-01 | 20.16M shares 10-K · filed 2014-02-21 | |
| 2011-01-02 | 25.02M shares 10-K · filed 2013-02-22 | |
| 2010-01-03 | 18.23K shares 10-K · filed 2012-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |